The Macular Minute Episode 12
with Hani Hasan, Rossella Anzidei and Richard Gale
Drying Effects of EYLEA® (aflibercept) 8 mg
In this 4-minute episode, we are joined by a panel of three consultant ophthalmologists to talk about their experience with the drying effects of EYLEA 8 mg.
This promotional podcast series has been organised and funded by Bayer and is for UK healthcare professionals only.
Prescribing information for EYLEA® (aflibercept) 8 mg can be found here.
Prescribing information for EYLEA® (aflibercept) 2 mg can be found here.
Speakers & Disclosures
Hani Hasan
Consultant Ophthalmologist at Newcastle upon Tyne Hospitals NHS Foundation Trust
Speaker Disclosures: Speaker and travel grants: AbbVie, Bayer and Roche
Rossella Anzidei
Consultant Ophthalmologist at University Hospitals Leicester NHS Trust
Speaker Disclosures: Speaker and travel grants: AbbVie, Bayer and Novartis
Richard Gale
Professor of Ophthalmology at York University and Honorary Consultant Ophthalmologist at Scarborough Teaching Hospitals NHS Foundation Trust
Speaker Disclosures: Speaker and travel grants: AbbVie, Alimera Sciences, Allergan, Amgen, Bayer, Biogen, Boehringer Ingelheim, Gilead Sciences, Heidelberg Pharma, Lux Biosciences, Notal Vision, Novartis, Roche, Santen
References
- PULSAR clinical trial: Lanzetta P et al. Lancet 2024; 403 (10432): 1141-1152.
- EYLEA® 40 mg/mL Summary of Product Characteristics.
- EYLEA® 114.3 mg/mL Summary of Product Characteristics.
PP-EYL-GB-2552 | December 2024